Financial Performance - The company's revenue for Q1 2023 reached ¥480,444,800.79, representing a 131.85% increase compared to ¥207,219,563.77 in the same period last year[4] - Net profit attributable to shareholders was ¥155,448,543.29, up 192.03% from ¥53,229,648.40 year-on-year[4] - Basic earnings per share rose to ¥2.43, reflecting a growth of 118.92% from ¥1.11 in the previous year[4] - Operating profit for Q1 2023 was ¥183,623,653.85, compared to ¥60,940,217.22 in Q1 2022, reflecting a growth of approximately 201%[20] - Net profit for Q1 2023 was ¥156,867,930.24, up from ¥53,229,648.40 in Q1 2022, representing an increase of about 195%[20] - Total comprehensive income attributable to minority shareholders for Q1 2023 is CNY 1,419,386.95, compared to CNY 0.00 in the previous period[21] - Basic and diluted earnings per share for Q1 2023 are both CNY 2.43, up from CNY 1.11 in the previous period, representing a 118.02% increase[21] Cash Flow - The net cash flow from operating activities was ¥76,241,811.79, an increase of 86.04% compared to ¥40,981,230.93 in Q1 2022[4] - Cash inflow from operating activities for Q1 2023 is CNY 435,919,191.93, a 95.00% increase from CNY 223,448,045.68 in the previous period[22] - Cash inflow from investment activities is CNY 1,581,783,945.90, significantly higher than CNY 280,354,022.48 in the previous period[23] - Cash outflow for investment activities totals CNY 1,692,097,686.36, compared to CNY 292,770,161.18 in the previous period[23] - Net cash flow from investment activities is -CNY 110,313,740.46, worsening from -CNY 12,416,138.70 in the previous period[23] - The company reported a net decrease in cash and cash equivalents of CNY 38,966,031.80 for Q1 2023[23] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥3,030,277,087.50, a 3.52% increase from ¥2,927,378,559.21 at the end of 2022[4] - Total liabilities decreased to ¥256,428,994.26 in Q1 2023 from ¥310,398,396.21 in the same period last year[17] - As of March 31, 2023, the company's total current assets amounted to ¥2,932,115,882.67, an increase from ¥2,848,918,930.94 at the beginning of the year, representing a growth of approximately 2.9%[15] - The company's cash and cash equivalents decreased to ¥317,147,107.19 from ¥356,113,138.99, reflecting a decline of about 10.9%[15] Shareholder Information - The total number of common shareholders at the end of the reporting period is 9,040[10] - The largest shareholder, Zhuang Zhi, holds 13.10% of shares, totaling 8,383,291 shares[10] - The second-largest shareholder, Zhuhai Hexuan Investment Center, holds 12.45%, amounting to 7,968,347 shares[10] - The third-largest shareholder, Chen Bei, owns 9.25% of shares, which is 5,917,948 shares[10] - The total number of shares held by the top ten shareholders represents a significant portion of the company's equity[10] - The largest foreign shareholder, Nengjin Co., Ltd., holds 6.00% of shares, equating to 3,838,225 shares[10] - The top ten shareholders include a mix of individual and institutional investors, indicating diverse ownership[10] - The report highlights that Zhuang Zhi and Xu Jian are acting in concert, which may influence shareholder dynamics[11] Research and Development - Research and development expenses increased by 76.35% to ¥19,539,134.96, driven by higher investment in R&D[9] - Research and development expenses for Q1 2023 were ¥19,539,134.96, up from ¥11,079,796.79 in Q1 2022, indicating a focus on innovation[20] Market Strategy - The company continues to focus on expanding its market presence and developing new technologies in the medical sector[14]
怡和嘉业(301367) - 2023 Q1 - 季度财报